Header Logo

Connection

Christopher Goetz to Adult

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Adult.
Christopher Goetz
Connection Strength
1.116
Adult
  1. Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). Mov Disord. 2017 Aug; 32(8):1244-1249.
    View in: PubMed
    Score: 0.059
  2. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.057
  3. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.050
  4. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014 Mar; 21(3):519-24.
    View in: PubMed
    Score: 0.047
  5. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015 Jan; 22(1):37-43.
    View in: PubMed
    Score: 0.045
  6. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.042
  7. Comparison of tic characteristics between children and adults. Mov Disord. 2008 Dec 15; 23(16):2407-11.
    View in: PubMed
    Score: 0.033
  8. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.033
  9. J.-M. Charcot and simulated neurologic disease: attitudes and diagnostic strategies. Neurology. 2007 Jul 03; 69(1):103-9.
    View in: PubMed
    Score: 0.030
  10. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.029
  11. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.027
  12. Thermography - a valuable tool to test hydrocephalus shunt patency. Acta Neurochir (Wien). 2005 Nov; 147(11):1167-72; discussion 1172-3.
    View in: PubMed
    Score: 0.026
  13. Medical-legal issues in Charcot's neurologic career. Neurology. 2004 May 25; 62(10):1827-33.
    View in: PubMed
    Score: 0.024
  14. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.022
  15. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
    View in: PubMed
    Score: 0.022
  16. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.020
  17. Home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome. Mov Disord. 2001 Jul; 16(4):693-7.
    View in: PubMed
    Score: 0.020
  18. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.019
  19. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
    View in: PubMed
    Score: 0.019
  20. Efficacy, tolerability, and safety of an innovative medical device for improving oral accessibility during oral examination in special-needs patients: A multicentric clinical trial. PLoS One. 2020; 15(9):e0239898.
    View in: PubMed
    Score: 0.019
  21. Impaired frontostriatal cognitive functioning following posteroventral pallidotomy in advanced Parkinson's disease. Brain Cogn. 2000 Apr; 42(3):348-63.
    View in: PubMed
    Score: 0.018
  22. Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Mov Disord. 1999 May; 14(3):502-6.
    View in: PubMed
    Score: 0.017
  23. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov Disord. 1998 May; 13(3):477-80.
    View in: PubMed
    Score: 0.016
  24. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6.
    View in: PubMed
    Score: 0.016
  25. Visibility and Depth of the Stromal Demarcation Line After Corneal Collagen Cross-Linking Using Anterior Segment Optical Coherence Tomography: Comparison Between Isoosmolar and Hypoosmolar Riboflavin. Cornea. 2018 May; 37(5):567-573.
    View in: PubMed
    Score: 0.016
  26. [Practical assessment of DSAEK in the management of endothelial decompensation following penetrating keratoplasty]. J Fr Ophtalmol. 2017 Dec; 40(10):844-852.
    View in: PubMed
    Score: 0.015
  27. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.015
  28. Intact mirror-tracing and impaired rotary-pursuit skill learning in patients with Huntington's disease: evidence for dissociable memory systems in skill learning. Neuropsychology. 1997 Apr; 11(2):272-81.
    View in: PubMed
    Score: 0.015
  29. The Mini-OAKHQOL for knee and hip osteoarthritis quality of life was obtained following recent shortening guidelines. J Clin Epidemiol. 2016 Jan; 69:70-8.
    View in: PubMed
    Score: 0.013
  30. Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Mov Disord. 1994 May; 9(3):315-7.
    View in: PubMed
    Score: 0.012
  31. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.011
  32. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10.
    View in: PubMed
    Score: 0.011
  33. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology. 1992 Apr; 42(4):784-8.
    View in: PubMed
    Score: 0.010
  34. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992 Apr; 42(4):878-82.
    View in: PubMed
    Score: 0.010
  35. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.009
  36. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med. 1989 Feb 09; 320(6):337-41.
    View in: PubMed
    Score: 0.008
  37. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
    View in: PubMed
    Score: 0.008
  38. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
    View in: PubMed
    Score: 0.008
  39. Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol. 1988; 49:185-97.
    View in: PubMed
    Score: 0.008
  40. Efficacy of cervical cord stimulation in dystonia. Adv Neurol. 1988; 50:645-9.
    View in: PubMed
    Score: 0.008
  41. Charcot at the Salp?tri?re: ambulatory automatisms. Neurology. 1987 Jun; 37(6):1084-8.
    View in: PubMed
    Score: 0.007
  42. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May; 37(5):875-8.
    View in: PubMed
    Score: 0.007
  43. Bromocriptine-induced myoclonus. Neurology. 1987 May; 37(5):885.
    View in: PubMed
    Score: 0.007
  44. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol. 1987 Mar; 21(3):307-10.
    View in: PubMed
    Score: 0.007
  45. The autonomic nervous system in Gilles de la Tourette's syndrome. Mov Disord. 1987; 2(2):99-102.
    View in: PubMed
    Score: 0.007
  46. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.007
  47. Autonomic dysfunction in Parkinson's disease. Neurology. 1986 Jan; 36(1):73-5.
    View in: PubMed
    Score: 0.007
  48. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.007
  49. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.007
  50. Bupropion in Parkinson's disease. Neurology. 1984 Aug; 34(8):1092-4.
    View in: PubMed
    Score: 0.006
  51. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.006
  52. Fluphenazine and multifocal tic disorders. Arch Neurol. 1984 Mar; 41(3):271-2.
    View in: PubMed
    Score: 0.006
  53. The pharmacology of olivopontocerebellar atrophy. Adv Neurol. 1984; 41:143-8.
    View in: PubMed
    Score: 0.006
  54. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003 Oct 14; 61(7):936-40.
    View in: PubMed
    Score: 0.006
  55. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.006
  56. On the mechanism of sudden death in Moersch-Woltman syndrome. Neurology. 1983 Jul; 33(7):930-2.
    View in: PubMed
    Score: 0.006
  57. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.006
  58. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.006
  59. Parkin mutations in a patient with hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study. Neurology. 2002 Mar 12; 58(5):808-10.
    View in: PubMed
    Score: 0.005
  60. Primary writing tremor: a selective action tremor. Neurology. 1982 Feb; 32(2):203-6.
    View in: PubMed
    Score: 0.005
  61. Gilles de la Tourette on Tourette syndrome. Adv Neurol. 1982; 35:1-16.
    View in: PubMed
    Score: 0.005
  62. Compressive neuropathies in Tourette syndrome. Adv Neurol. 1982; 35:345-7.
    View in: PubMed
    Score: 0.005
  63. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.005
  64. Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov; 31(11):1460-2.
    View in: PubMed
    Score: 0.005
  65. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
    View in: PubMed
    Score: 0.005
  66. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
    View in: PubMed
    Score: 0.005
  67. Gilles de la Tourette syndrome and compressive neuropathies. Ann Neurol. 1980 Oct; 8(4):453.
    View in: PubMed
    Score: 0.005
  68. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999 Sep 23; 341(13):988-92.
    View in: PubMed
    Score: 0.004
  69. Movement disorders in Kuru. Mov Disord. 1999 Sep; 14(5):800-4.
    View in: PubMed
    Score: 0.004
  70. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.004
  71. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.004
  72. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.004
  73. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm (Vienna). 1998; 105(2-3):217-27.
    View in: PubMed
    Score: 0.004
  74. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
    View in: PubMed
    Score: 0.004
  75. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol. 1996 Sep; 40(3):463-5.
    View in: PubMed
    Score: 0.004
  76. Neuropsychological deficits in patients with Sneddon's syndrome. J Neurol. 1996 Apr; 243(4):357-63.
    View in: PubMed
    Score: 0.003
  77. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995 Aug; 18(4):338-47.
    View in: PubMed
    Score: 0.003
  78. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995 Jun; 52(6):565-70.
    View in: PubMed
    Score: 0.003
  79. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
    View in: PubMed
    Score: 0.003
  80. Renal complications of infected ventriculoatrial shunts. Artif Organs. 1993 Aug; 17(8):695-701.
    View in: PubMed
    Score: 0.003
  81. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.002
  82. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989 Oct; 12(5):375-83.
    View in: PubMed
    Score: 0.002
  83. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 1989 May; 39(5):660-4.
    View in: PubMed
    Score: 0.002
  84. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
    View in: PubMed
    Score: 0.002
  85. Hemiparkinsonism with hemiatrophy. Neurology. 1988 Apr; 38(4):527-30.
    View in: PubMed
    Score: 0.002
  86. The predictive value of acute antimuscarinic drugs for the chronic efficacy of antimuscarinic drugs in adults with focal dystonia. Adv Neurol. 1988; 50:557-60.
    View in: PubMed
    Score: 0.002
  87. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
    View in: PubMed
    Score: 0.002
  88. Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol. 1987; 45:547-9.
    View in: PubMed
    Score: 0.002
  89. Speech abnormalities in tardive dyskinesia. Arch Neurol. 1984 Mar; 41(3):273-6.
    View in: PubMed
    Score: 0.001
  90. Cholinergic mechanisms in Tourette syndrome. Neurology. 1982 Nov; 32(11):1315-7.
    View in: PubMed
    Score: 0.001
  91. Pergolide mesylate and idiopathic Parkinson disease. Neurology. 1982 Oct; 32(10):1175-9.
    View in: PubMed
    Score: 0.001
  92. Tardive dyskinesia: review and update. Am J Psychiatry. 1980 Aug; 137(8):900-8.
    View in: PubMed
    Score: 0.001
  93. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med. 1978 Mar; 88(3):327-31.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.